Mechanism of Action at the Molecular Level
Benzodiazepines work by enhancing GABAergic inhibition. They do not replace the neurotransmitter GABA itself; instead, they bind to a specific allosteric site—the benzodiazepine receptor. This site is formed by the α and γ subunits of the supramolecular GABA-A complex.
Events following receptor activation:
- Conformational change of the GABA receptor.
- Increased sensitivity to gamma-aminobutyric acid.
- Increased frequency of chloride channel opening.
- Massive influx of chloride ions (Cl-) into the neuron, causing membrane hyperpolarization.
Result: Marked neuronal inhibition. This mechanism underlies the suppression of epileptiform activity (anticonvulsant effect). The exact mechanism of central muscle relaxation remains incompletely understood, but the leading hypothesis involves the inhibition of polysynaptic spinal reflexes and disruption of their supraspinal regulation.
Pharmacological Effects and Receptors
Drug effects depend on which specific receptor subunits they bind to. Two main types of ω-receptors are recognized:
- ω1 Receptors (contain the α1 subunit): Mediate sedative and amnestic effects.
- ω2 Receptors (contain α2, α3, or α5 subunits): Mediate anxiolytic (antianxiety) effects.
Classic benzodiazepines act non-selectively, activating both types. This distinguishes them from Z-drugs (e.g., zolpidem), which selectively bind only to ω1 receptors and act primarily as hypnotics.
In total, the group exhibits five major effects: anxiolytic, sedative, hypnotic, anticonvulsant, and central muscle relaxant. These effects are dose-dependent: low doses produce sedation, higher doses induce sleep, and very large doses can lead to anterograde amnesia (loss of memory for events occurring after administration).
In clinical practice, these effects dictate indications for use: neurotic disorders with fear and anxiety, insomnia, epilepsy, conditions with increased muscle tone, as well as premedication and induction in anesthesiology.
Pharmacokinetic Features
These drugs are highly lipophilic; therefore, they are readily absorbed in the duodenum and significantly sequestered in adipose tissue. In the blood, 70–90% is bound to plasma proteins.
A key feature of hepatic metabolism (oxidation followed by conjugation) is the formation of active metabolites, which have a significantly longer duration of action than the parent compound. For example, the half-life of N-desmethyldiazepam reaches 40–200 hours.
Typical metabolic chain: diazepam or chlordiazepoxide are converted to desmethyldiazepam and then to oxazepam. Oxazepam is a terminal active metabolite, but it is also used clinically as an independent medication. Elimination occurs primarily via the kidneys.
There are differences in potency among the agents. Phenazepam and diazepam are potent anxiolytics and hypnotics, with phenazepam exceeding diazepam in potency. Chlordiazepoxide has less pronounced effects.
Adverse Effects and Toxicity
Despite their high efficacy, benzodiazepines require strict dosing and limited duration of use.
- Dependence and Tolerance: These agents can induce euphoria, leading to abuse potential. With prolonged use, efficacy decreases, requiring dose escalation.
- Withdrawal Syndrome: Occurs even after a short course. Manifests as anxiety, insomnia, depression, nausea, and perceptual disturbances. Symptoms can persist for months.
- Cognitive and Motor Impairment: Somnolence, headache, memory impairment, and coordination deficits (ataxia). These are particularly pronounced in elderly patients.
- Neonatal Toxicity: The drugs cross into breast milk, causing CNS depression in infants (lethargy, feeding difficulties, weight loss).
Acute overdose presents with lethargy, pronounced somnolence, ataxia, and in severe cases, coma. Administration of a specific antidote is required.